Total Payments
$69,442
2024 Payments
$62.89
Companies
24
Transactions
295
Payment Breakdown by Category
Research$45,232 (65.1%)
Consulting$12,720 (18.3%)
Other$5,362 (7.7%)
Food & Beverage$4,650 (6.7%)
Travel$1,287 (1.9%)
Education$190.50 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $45,232 | 32 | 65.1% |
| Consulting Fee | $12,720 | 4 | 18.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,063 | 2 | 7.3% |
| Food and Beverage | $4,650 | 248 | 6.7% |
| Travel and Lodging | $1,287 | 4 | 1.9% |
| Honoraria | $300.00 | 1 | 0.4% |
| Education | $190.50 | 4 | 0.3% |
Payments by Type
Research
$45,232
32 transactions
General
$24,210
263 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Vanda Pharmaceuticals Inc. | $40,500 | 3 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $11,882 | 41 | $0 (2022) |
| Allergan, Inc. | $5,557 | 38 | $0 (2020) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,736 | 16 | $0 (2021) |
| Neurocrine Biosciences, Inc. | $2,485 | 2 | $0 (2018) |
| Lundbeck LLC | $1,320 | 82 | $0 (2020) |
| ACADIA Pharmaceuticals Inc | $1,167 | 11 | $0 (2020) |
| Janssen Research & Development, LLC | $772.09 | 9 | $0 (2018) |
| Vyera Pharmaceuticals, LLC | $500.00 | 1 | $0 (2017) |
| ABBVIE INC. | $463.46 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $62.89 | 2 | ABBVIE INC. ($62.89) |
| 2023 | $22,038 | 9 | Vanda Pharmaceuticals Inc. ($21,750) |
| 2022 | $11,195 | 6 | Sunovion Pharmaceuticals Inc. ($11,120) |
| 2021 | $19,057 | 15 | Vanda Pharmaceuticals Inc. ($18,750) |
| 2020 | $1,480 | 28 | ACADIA Pharmaceuticals Inc ($1,167) |
| 2019 | $3,867 | 91 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($2,674) |
| 2018 | $8,909 | 75 | Allergan Inc. ($5,165) |
| 2017 | $2,834 | 69 | Neurocrine Biosciences, Inc. ($884.80) |
All Payment Transactions
295 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $49.30 | General |
| 12/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.59 | General |
| Category: NEUROSCIENCE | ||||||
| 12/05/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $37.18 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $18.85 | General |
| 09/07/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $31.82 | General |
| Category: NEUROSCIENCE | ||||||
| 08/02/2023 | Biogen, Inc. | — | Education | In-kind items and services | $61.50 | General |
| 08/02/2023 | Biogen, Inc. | — | Education | In-kind items and services | $51.50 | General |
| 08/02/2023 | Biogen, Inc. | — | Education | In-kind items and services | $42.50 | General |
| 06/09/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: NEUROSCIENCE | ||||||
| 05/18/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: NEUROSCIENCE | ||||||
| 01/04/2023 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $21,750.00 | Research |
| Study: EVALUATING THE EFFECTS OF VQW-765 VS. PLACEBO IN PERFORMANCE ANXIETY | ||||||
| 11/03/2022 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 10/06/2022 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $3,360.00 | General |
| 09/15/2022 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $2,760.00 | General |
| 05/17/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: NEUROSCIENCE | ||||||
| 04/08/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.77 | General |
| Category: NEUROSCIENCE | ||||||
| 02/14/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: NEUROSCIENCE | ||||||
| 10/27/2021 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $6,250.00 | Research |
| Study: EVALUATING THE EFFECTS OF VQW-765 VS. PLACEBO IN PERFORMANCE ANXIETY | ||||||
| 10/19/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: NEUROSCIENCE | ||||||
| 09/29/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: NEUROSCIENCE | ||||||
| 09/20/2021 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $62.50 | General |
| 09/09/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.41 | General |
| Category: NEUROSCIENCE | ||||||
| 09/02/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: NEUROSCIENCE | ||||||
| 08/15/2021 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $12.86 | General |
| Category: NEUROSCIENCE | ||||||
| 07/21/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.52 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EVALUATING THE EFFECTS OF VQW-765 VS. PLACEBO IN PERFORMANCE ANXIETY | Vanda Pharmaceuticals Inc. | $40,500 | 3 |
| A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,386 | 9 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,288 | 6 |
| ACP-103-059/ACP-103-055 | ACADIA Pharmaceuticals Inc | $1,167 | 11 |
| TUR-002 | Vyera Pharmaceuticals, LLC | $500.00 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy, Safety, and Tolerability of Multiple Subcutaneous Injections of Depot Buprenorphine RBP-6000 100 mg and 300 mg Over 24 Weeks in Treatment-Seeking Subjects With Opioid Use Disorder | Indivior Inc. | $388.40 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $2.83 | 1 |
About Dr. Michael Liebowitz, MD
Dr. Michael Liebowitz, MD is a Psychiatry healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1265578629.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Liebowitz, MD has received a total of $69,442 in payments from pharmaceutical and medical device companies, with $62.89 received in 2024. These payments were reported across 295 transactions from 24 companies. The most common payment nature is "" ($45,232).
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Psychiatry
- Location New York, NY
- Active Since 01/30/2007
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1265578629
Products in Payments
- BOTOX (Biological) $5,000
- REXULTI (Drug) $3,233
- INGREZZA (Drug) $2,485
- NUPLAZID (Drug) $1,167
- VRAYLAR (Drug) $881.43
- LATUDA (Drug) $761.54
- SUBLOCADE (Drug) $388.40
- TRINTELLIX (Drug) $308.34
- Trintellix (Drug) $271.73
- SPRAVATO (Drug) $99.85
- BELSOMRA (Drug) $59.12
- NUEDEXTA (Drug) $50.42
- VYVANSE (Drug) $49.82
- SUNOSI (Drug) $32.83
- BRINTELLIX (Drug) $22.31
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $17.74
- INVEGA SUSTENNA (Drug) $13.56
- AUSTEDO (Drug) $12.63
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in New York
Dr. Manish Zinzuvadia, M.d, M.D
Psychiatry — Payments: $1.3M
Psychiatry $1.3M
Dr. Jianping Chen, M.d, M.D
Psychiatry — Payments: $1.1M
Psychiatry $1.1M
Dr. Ulla Laakso, Md, MD
Psychiatry — Payments: $957,236
Psychiatry $957,236
Dr. Kerry Sulkowicz, M.d, M.D
Psychiatry — Payments: $476,134
Psychiatry $476,134
Dr. Ralph Aquila, M.d, M.D
Psychiatry — Payments: $327,213
Psychiatry $327,213
Dr. Paul Eder, M.d, M.D
Psychiatry — Payments: $278,989
Psychiatry $278,989